Canada remains the ninth largest pharmaceutical market in the world, close to Spain and the United Kingdom. Drug makers operating in Canada have benefited from high per capita spending on pharmaceuticals and rising procurement as a result of the country’s aging population. In 2014 alone, the country spent an estimated $28.8 billion on prescribed drugs.¹ Moreover, Canada’s private payer system, which covers as much as two-thirds of the country’s population, has been far less restrictive than market-access decision-makers in many European markets.² These stats, taken together, show how the Canadian market has historically offered most manufacturers the potential for profitability.